This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Multiple Congenital Exostoses (Hereditary Multiple Exostoses)다발성 선천외골증 (다발성선천외골증)

📋 Contents and key points
ItemDetails
A. Classification codesICD-10: Q78.6 (Multiple congenital exostoses) | Special Copayment Reduction: V242
B. SynonymsMultiple congenital exostoses, diaphyseal aclasis, hereditary multiple exostoses, Hereditary Multiple Osteochondromatosis, EXT syndrome
C. Adult onsetLikelihood of first onset in adulthood: low — Exostoses are found in childhood (mostly before age 10), but nerve or vascular compression complications may first become symptomatic in adulthood, or malignant transformation (chondrosarcoma) may be diagnosed in adulthood.
1. History1786: first described by Boyer → 1891: Virchow defined the pathology of osteochondroma → 1954: unified as hereditary multiple exostoses → 1993–95: EXT1/EXT2 genes identified.
2. CausesVariants in the EXT1 (8q24.1) or EXT2 (11p11-12) gene impair heparan sulfate biosynthesis → abnormal proliferation of growth plate chondrocytes and exostosis formation. Autosomal dominant (AD).
3. GeneticsEXT1 (8q24, tumor suppressor gene), EXT2 (11p12). Osteochondromas form with loss of the second allele (two-hit model). EXT1 variants carry a higher risk of malignant transformation than EXT2.
4. General epidemiologyPrevalence about 1/50,000. Males slightly more often affected. Malignant transformation to chondrosarcoma: EXT1 about 2–5%, EXT2 about 0.5–1%.
5. PathophysiologyLoss of heparan sulfate polymerase function of the EXT1/EXT2 protein complex → disruption of IHH and FGF signaling → loss of growth plate chondrocyte orientation → osteochondromas sprouting from the lateral metaphysis.
6. SymptomsBony protrusions around the metaphysis (painless to painful), skeletal deformities (shortening and bowing of the forearm, genu valgum), nerve compression (radial nerve palsy, etc.), vascular compression. Malignant transformation suspected if an osteochondroma continues to grow after growth is complete.
7. SignsPalpable hard bony projections; on X-ray, bony protrusions covered by a cartilage cap growing from the metaphysis away from the bone. On MRI, cartilage cap thickness >1.5–2 cm is a warning of malignant transformation.
8. ScreeningClinical and radiological screening based on family history. Whole-skeleton evaluation from childhood in children of affected parents. Molecular testing of the EXT1/EXT2 genes. Prenatal diagnosis possible.
9. DiagnosisX-ray (multiple metaphyseal osteochondromas), MRI (cartilage cap thickness), EXT1/EXT2 gene analysis. Assessment of malignant transformation: CT, bone scan, tissue biopsy.
10. TreatmentExcision of symptomatic osteochondromas. Correction of skeletal deformities (osteotomy, external fixation). Emergency excision with nerve or vascular compression. Wide resection upon malignant transformation. Regular surveillance (MRI/CT).
11. PrognosisNormal life expectancy. Surveillance for complications important. Risk of malignant transformation higher with EXT1 than with EXT2. New growth or a rapid increase in size of an osteochondroma after growth is complete is a warning sign of malignant transformation.
12. PreventionGenetic counseling, PGT/prenatal diagnosis. Regular imaging surveillance (early detection of malignant transformation). Early correction of skeletal deformities during growth.
13. ReferencesWicklund CL et al. (1995), Stickens D et al. (1996) identification of the EXT1/EXT2 genes … and 9 other papers

1. History

The history of Multiple Congenital Exostoses (MCE; also Hereditary Multiple Osteochondromatosis) has developed over centuries. The oldest record is known to be the description in 1786 by the French surgeon Boyer of protruding lesions growing from the bone surface, and in 1891 the German pathologist Rudolf Virchow named this lesion osteochondroma and first systematically described its histological features, including the cartilage covering. Virchow intuitively grasped that this lesion originates from the growth plate of bone, which remains the basis of a valid etiology today.

Recognition as a hereditary disease began in the late 19th century, with accumulating reports of families in which multiple osteochondromas occurred repeatedly in the same kindred. In 1913, Keith redefined this disease including osteochondromas from the perspective of a "congenital anomaly", and in the 1950s an autosomal dominant mode of inheritance was confirmed through genetic epidemiological studies. The name "diaphyseal aclasis" was also widely used in the United Kingdom, emphasizing a pathological disorder of bone modeling.

A landmark turning point in molecular genetics came in 1993–1995. In 1993, Langer et al. first mapped the causative gene locus of hereditary multiple exostoses to the long arm of chromosome 8 (8q24), and in 1994 Wuyts et al. identified a second locus on the short arm of chromosome 11 (11p12). In 1995, Stickens et al. and Ahn et al. independently cloned the EXT1 gene, and in 1996 Wuyts et al. identified the EXT2 gene. It was subsequently revealed that the two genes form a glycosyltransferase complex involved in heparan sulfate (HS) biosynthesis, elucidating at the molecular level the link between heparan sulfate proteoglycan abnormalities and disorders of skeletal development. OMIM currently lists EXT1-related MCE (OMIM #133700) and EXT2-related MCE (OMIM #133701) separately.

In Korea, patients with multiple congenital exostoses are classified as having a rare skeletal dysplasia and receive Special Copayment Reduction (V242) benefits, and many cases are diagnosed and managed in pediatric orthopedics and medical genetics. Systematic studies of domestic prevalence are limited, but familial cases continue to be reported, centered on large hospitals in Seoul and the capital region.

2. Causes

Multiple congenital exostoses is an autosomal dominant (AD) genetic disease caused by germline variants of the EXT1 or EXT2 gene. The EXT1 gene is located on the long arm of chromosome 8 (8q24.11) and the EXT2 gene on the short arm of chromosome 11 (11p12). Both genes encode glycosyltransferases essential for heparan sulfate (HS) chain polymerization, and the two proteins form a complex that catalyzes the elongation of HS chains of heparan sulfate proteoglycans (HSPGs) in the Golgi.

EXT1 variants are identified in about 55–75% of all MCE patients, and EXT2 variants in about 20–30%. The remaining about 5–15% are cases in which no currently known EXT1/EXT2 variant is identified, and additional genetic heterogeneity is presumed. Reported variant types include frameshift, nonsense, missense, splicing variants, and large deletions, distributed throughout the genes without specific mutation clusters. In about 10–20% of patients, a de novo mutation without a family history is identified.

The severity of the clinical phenotype and the risk of malignant transformation differ according to the causative gene. Patients with EXT1 variants have more osteochondromas, more severe skeletal deformities, and a significantly higher risk of malignant transformation to chondrosarcoma than patients with EXT2 variants (EXT1: about 2–5%, EXT2: about 0.5–1%). EXT1 also functions as a tumor suppressor gene, and somatic loss of the second EXT1 allele (two-hit hypothesis) is proposed as the key mechanism of monoclonal proliferation of osteochondromas and potential malignant transformation. In patients with EXT2 variants, symptoms are relatively mild and the frequency of malignant transformation is low.

Because inheritance is autosomal dominant, children of affected patients have a 50% chance of inheriting the disease. Affected males outnumber females (M:F = about 1.5:1), and even with the same genotype, phenotypic differences between individuals are large (variable expressivity). This is explained by differences in the timing and location of somatic second hits, genetic background, and modifier genes.

3. Genetics

The EXT1 gene is located on the long arm of chromosome 8 (8q24.11) and consists of 11 exons. Its protein product, Exostosin-1, consists of 919 amino acids and is a type II transmembrane protein located in the Golgi membrane. EXT1 has dual enzymatic activity as a heparan sulfate glucuronosyltransferase and N-acetylglucosamine transferase (GlcNAc transferase), catalyzing the repeated elongation of disaccharide units of HS chains. The EXT2 gene is located on the short arm of chromosome 11 (11p12), and its protein, Exostosin-2, consists of 718 amino acids. EXT1 and EXT2 are synthesized together in the endoplasmic reticulum (ER) and then form a heterodimer complex that moves to the Golgi, exerting maximal enzymatic activity only in this complex form.

Heparan sulfate proteoglycans (HSPGs) act as co-receptors essential for growth factor signaling by Indian Hedgehog (IHH), fibroblast growth factors (FGF), Wnt ligands, and others. When HSPG biosynthesis is reduced by loss of EXT1/EXT2 function, normal gradient formation and localization of these signaling pathways are disrupted, perturbing the normal directionality of differentiation of growth plate chondrocytes. Specifically, abnormalities of the IHH-PTHrP (parathyroid hormone-related protein) feedback loop cause chondrocytes to escape from the growth plate and form osteochondromas on the metaphyseal surface.

The two-hit model applies to the formation of individual osteochondromas. The theory is that, in a state where the function of one allele of EXT1 or EXT2 has been lost through a germline variant, when a somatic variant (second hit) additionally occurs in a particular growth plate chondrocyte, HSPG biosynthesis is completely blocked in that cell and an osteochondroma forms. As supporting evidence, somatic loss of the normal allele (loss of heterozygosity, LOH) has been repeatedly confirmed in resected osteochondroma tissue. Because EXT1 also functions as a tumor suppressor gene, it is understood that patients with EXT1 variants have more multiple osteochondromas and a higher risk of malignant transformation. If EXT1/EXT2 variants are not identified on molecular genetic testing, the possibility of variants in other genes of the HSPG biosynthesis pathway, such as EXT3, EXTL1, and EXTL3, should be considered.

In genetic counseling, owing to the nature of autosomal dominant inheritance, 50% of the children of an affected parent inherit the gene variant, but penetrance is nearly 100%, and children carrying the variant are known to eventually develop osteochondromas. However, the number, size, and location of osteochondromas and whether complications develop vary greatly between individuals even within the same family. In families with molecular confirmation, only unaffected embryos can be implanted through preimplantation genetic testing (PGT), and PGT for MCE is currently performed at some institutions.

4. General epidemiology

Multiple congenital exostoses is relatively common among rare skeletal dysplasias, with a reported prevalence of about 1/50,000–1/100,000. However, including mild cases and undiagnosed patients, the actual prevalence is estimated to be higher. There are an estimated 10,000–30,000 patients worldwide, with the most reported cases in Europe and North America. Owing to autosomal dominant inheritance, it occurs multiply in certain families, with marked familial clustering.

In sex distribution, males tend to be affected slightly more often than females (M:F = about 1.4–1.7:1). The cause of this sex difference has not been clearly identified, but the inhibitory effect of estrogen on osteochondroma growth and the influence of X-linked modifier genes have been proposed as hypotheses. EXT1 or EXT2 variants are identified in about 62–96% of all patients, and in the rest no currently known variant is detected. About 10–20% arise from de novo mutations without a family history.

The epidemiology of malignant transformation is clinically very important. The risk of malignant transformation to chondrosarcoma in all MCE patients is reported as about 1–5%, but it differs greatly depending on the causative gene. The risk of malignant transformation is known to be about 2–5% in patients with EXT1 variants and about 0.5–1% in patients with EXT2 variants. Malignant transformation mainly occurs in adulthood (20s–40s) and is observed more often at sites close to the trunk (axial skeleton), such as the pelvis, scapula, spine, and proximal femur. A characteristic of MCE is that it is significantly higher than malignant transformation of solitary osteochondromas (< 1%).

In Korea, MCE is classified as a rare skeletal dysplasia and is eligible for Special Copayment Reduction (V242) registration. Official data on domestic prevalence and the number of registered patients are limited, but familial MCE cases continue to be diagnosed at major university-affiliated hospitals in Korea. Systematic research on the EXT1/EXT2 variant spectrum and clinical phenotypic features in Korean MCE patients is needed going forward.

5. Pathophysiology

The pathogenic mechanism of multiple congenital exostoses is impaired heparan sulfate proteoglycan (HSPG) biosynthesis due to loss of EXT1/EXT2 gene function and the resulting disruption of growth factor signaling pathways. In a normal growth plate, columns of chondrocytes (columnar organization) that proliferate, mature, and hypertrophy toward the metaphysis are formed, and in this process IHH (Indian hedgehog signaling protein), PTHrP, FGF (fibroblast growth factor), and BMP (bone morphogenetic protein) signals are precisely regulated through HSPGs. HSPGs play a key role in forming signal gradients (morphogen gradients) by binding growth factors directly or mediating interactions with growth factor receptors.

A variant in one EXT1 or EXT2 allele reduces HSPG biosynthesis by half but has no major clinical effect. However, when the second allele also loses function through a somatic mutation in a particular growth plate chondrocyte (two-hit), HSPG biosynthesis is completely blocked in that cell. Chondrocytes that have lost HSPGs cannot recognize IHH signals normally, escape regulation by the PTHrP-IHH negative feedback loop, and begin to proliferate outward from the growth plate. This 'derailed' chondrocyte clone forms a cartilage cap on the metaphyseal surface, and as normal bone maturation proceeds beneath it, a bony stalk forms through endochondral ossification. This is the process of formation of the histological structure of an osteochondroma (cartilage cap + bony stalk + continuity with the medullary cavity).

The direction in which osteochondromas grow toward the growth plate (growth direction away from the joint) stems from a vector pointing toward the growth plate, opposite to the normal direction of bone growth. Until growth is complete, the growth plate is active, so osteochondromas also grow, and growth generally stops after closure of the growth plate. If new growth appears or an existing osteochondroma enlarges rapidly even after growth is complete, the possibility of malignant transformation to chondrosarcoma must be considered. With malignant transformation, the cartilage cap thickens (1.5–2 cm or more on MRI), irregular calcification appears, and findings of infiltration of surrounding tissue are observed.

The mechanism of skeletal deformity is also related to HSPG abnormalities. When osteochondromas form between the radius and ulna, the growth rates of the two bones become unbalanced, resulting in forearm shortening, radioulnar joint dislocation, and wrist flexion deformity. Around the knee, fibular osteochondromas press on the tibia or interfere with medial growth, causing genu valgum. Particular caution is needed because spinal cord compression can occur when osteochondromas of the spine invade the spinal canal.

6. Symptoms

The clinical symptoms of multiple congenital exostoses vary greatly depending on the number, size, location, and growth rate of osteochondromas and their relationship with surrounding structures (nerves, blood vessels, ligaments, joints). Symptoms appear in various forms from childhood through adulthood, and after growth is complete new osteochondromas rarely develop, but complications of existing lesions may continue to occur.

The most common symptom is a bony prominence around the metaphysis. Hard, immobile bony nodules form mainly around the knee (distal femur, proximal tibia), ankle, around the shoulder (scapula, proximal humerus), and forearm (radius and ulna). They range in size from a few millimeters to several centimeters and are often painless, but when friction or compression of surrounding tendons, bursae, nerves, or blood vessels occurs, pain, sensory abnormalities, and limitation of movement appear. Pain often worsens especially during activity or in certain positions.

Skeletal deformity is a representative long-term complication of MCE. Forearm deformity (forearm shortening, wrist flexion, radioulnar joint dislocation) results from unbalanced growth of the radius and ulna and, especially if it begins at a young age, gradually worsens until growth is complete. Genu valgum is caused by proximal tibial osteochondromas, leading to lower-limb malalignment and gait abnormalities. Reduced height, leg length discrepancy, and scoliosis have also been reported.

Nerve and vascular compression are rare but serious complications. Radial nerve compression can cause wrist drop, digital nerve compression can cause sensory abnormalities, and compression of the popliteal nerve plexus can cause foot drop. Lower-limb ischemia may occur with compression of the popliteal vessels, and when an osteochondroma around the spinal cord directly compresses the cord, myelopathic symptoms (lower-limb paralysis, urinary incontinence) appear. These nerve and vascular complications require immediate surgical treatment. If an existing osteochondroma suddenly increases in size or new pain develops after growth is complete, malignant transformation (chondrosarcoma) must be suspected.

7. Signs

The physical signs of multiple congenital exostoses are palpable, hard, immobile bony protrusions observed at multiple sites. On palpation through the skin, they have a hard, smooth surface, are not adherent to the skin, and are firmly fixed to the base (bone). They range in size from a few millimeters to several centimeters, and thickening of surrounding soft tissue or bursa formation may accompany them, so they may feel larger on palpation than they actually are. Joint range of motion may be limited, or locking (mechanical block) symptoms may appear at certain angles.

Radiological signs are key to diagnosis. X-ray shows bony lesions protruding from the metaphysis beyond the bone surface, characteristically with the stalk continuous with the cortex and medullary cavity of the parent bone. The cartilage cap is radiolucent on X-ray and therefore not directly visible, but stippled calcification within the cap may be seen. Lesions appear as pedunculated (with a stalk) or sessile (with a broad base). In pedunculated osteochondromas, the stalk characteristically points away from the joint (away from the growth plate).

MRI findings are essential for assessing cartilage cap thickness. The cartilage cap thickness of a normal osteochondroma is up to 3 cm in children and less than 1.5 cm in adults, and in adults a cartilage cap of 1.5–2 cm or more is regarded as a warning sign of malignant transformation (chondrosarcoma). In addition, MRI findings such as irregular signal intensity of the cartilage cap, changes in calcification pattern, and infiltration of surrounding soft tissue are associated with malignant transformation. MRI or CT is also used for accurate anatomical assessment when nerve or vascular compression is suspected. On bone scan, osteochondromas show increased radioisotope uptake during growth, but persistent uptake after growth is complete suggests malignant transformation.

Blood and biochemical tests generally show no abnormal findings. When malignant transformation has progressed, LDH, alkaline phosphatase (ALP), and the like may be elevated, but this is not specific. Tissue biopsy is performed when malignant transformation is suspected and is used to assess the grade of chondrosarcoma.

8. Screening

Screening of all newborns for multiple congenital exostoses is not performed. However, because of autosomal dominant inheritance, children of affected parents have a 50% chance of inheriting the variant, so a systematic screening approach is important when there are affected family members.

Clinical and radiological screening: Children of affected parents undergo whole-skeleton X-rays and physical examination from childhood (age 3–5) to periodically assess whether osteochondromas have developed. A whole-skeleton X-ray (skeletal survey) images bones throughout the body, including the long bones of the limbs, flat bones, and spine, to identify the characteristic metaphyseal bony protrusions. Ultrasound can be used to noninvasively evaluate the relationship between soft tissue and the bone surface but has limitations for systemic assessment. During growth, follow-up radiological examinations every 1–2 years monitor changes in existing lesions and the development of new lesions.

Molecular genetic screening: When an EXT1 or EXT2 variant in the family has been confirmed at the molecular level, early molecular confirmation is possible for children or at-risk family members by directly detecting the target variant in blood. In families where the variant has not been identified, NGS-based EXT1/EXT2 gene panel testing or whole-exome sequencing (WES) is used as a diagnostic tool. Molecular diagnosis helps establish a follow-up plan by determining whether a person is affected before the clinical phenotype appears.

Prenatal diagnosis and preimplantation genetic testing: When the familial variant has been identified, prenatal diagnosis is possible through CVS (11–14 weeks) or amniocentesis (15–20 weeks). PGT is a method of preventing the birth of an affected child by implanting only unaffected embryos. However, because MCE has a relatively favorable prognosis in the absence of malignant transformation, the decision about PGT should be made after thorough genetic counseling and in light of the values of the patient and family. PGT is more often chosen in families with EXT1 variants, in which the risk of malignant transformation is higher.

9. Diagnosis

Diagnosis of multiple congenital exostoses is made by clinical findings, radiological findings, and molecular genetic confirmation. The clinical diagnostic criteria consist of ① the presence of two or more osteochondromas, ② multiple distribution (mainly the metaphyses of long bones), and ③ a family history (autosomal dominant) or a de novo variant. Unlike solitary osteochondroma, multiple lesions are characteristic of MCE, and clinical diagnosis is relatively easy when several family members are affected.

Whole-skeleton X-ray is the primary diagnostic tool. The long bones of both limbs (femur, tibia, fibula, humerus, radius, ulna), flat bones (scapula, pelvis), and entire spine are imaged to identify osteochondromas protruding from the metaphysis beyond the bone surface. In MCE, symmetric and multiple osteochondromas are observed at the metaphyses of long bones throughout the body. They are pedunculated or sessile, and continuity of the cortex and medullary cavity with the parent bone is the key X-ray feature for diagnosing osteochondroma. Differentiation from solitary osteochondroma, chondrosarcoma, enchondromatosis (Ollier disease), Maffucci syndrome, and others is needed.

MRI is used to assess cartilage cap thickness, nerve and vascular compression, and malignant transformation. In adults, a cartilage cap thickness of 1.5 cm or more is a warning sign of malignant transformation, and irregular margins of the cap, soft tissue infiltration, and changes in the existing calcification pattern also suggest malignant transformation. CT is used for three-dimensional assessment of bone structure and surgical planning and is especially useful for lesions of the spine, pelvis, and scapula. Bone scan is used to identify sites of growth activity and when malignant transformation is suspected. In lesions suspected of malignant transformation, the presence and grade of chondrosarcoma (low grade 1 and 2 vs. high grade 3) are confirmed histologically by tissue biopsy (incisional or needle biopsy).

EXT1/EXT2 gene analysis is the standard for molecular confirmation. Sanger sequencing, MLPA (multiplex ligation-dependent probe amplification), and NGS-based gene panel testing are used. Identification of a pathogenic EXT1 or EXT2 variant confirms the diagnosis, and identification of the causative gene is important for predicting the risk of malignant transformation and for genetic counseling. If no EXT1/EXT2 variant is identified, further investigation is possible with whole-exome or whole-genome analysis.

10. Treatment

No curative treatment (gene or drug) for multiple congenital exostoses is yet available clinically, and the current standard of treatment is a symptom-focused multidisciplinary approach aimed at symptom relief, prevention of complications, correction of skeletal deformities, and surveillance for malignant transformation.

Surgical excision is the main treatment method. Asymptomatic osteochondromas do not necessarily need to be excised and are managed with regular surveillance. Surgical excision is performed for symptomatic osteochondromas (pain, nerve or vascular compression, limitation of joint motion, recurrent bursitis, cosmetic problems). Complete removal of the base (the entire cartilage cap including the stalk) is important to prevent recurrence, and regrowth of residual osteochondroma may occur after incomplete excision. Prompt excision is needed when there is nerve or vascular compression, and emergency surgery is performed especially when spinal cord compression has occurred.

Correction of skeletal deformities is also an important treatment goal. For forearm deformities (forearm shortening, wrist flexion), strategies such as gradual correction during growth using osteotomy and an external fixator, or simple observation after excision of the relevant osteochondroma, are individualized for each patient. Genu valgum is corrected by hemiepiphysiodesis or osteotomy. When scoliosis is present, bracing or surgical correction is needed. When leg length discrepancy is severe, bone lengthening or growth plate arrest on the unaffected side are options.

Surveillance for malignant transformation is one of the most important elements of MCE management. After growth is complete, monitoring of cartilage cap thickness with MRI every 1–2 years is recommended, and stricter follow-up is needed especially for lesions at sites close to the trunk (pelvis, scapula, spine). If an existing osteochondroma newly grows or rapidly increases in size in adulthood, or new pain develops, immediate MRI and CT evaluation together with tissue biopsy should be considered. If malignant transformation is confirmed, wide resection as for chondrosarcoma is the principle of treatment, and because radiation and chemotherapy are generally not effective in low-grade chondrosarcoma, surgical resection is the first-line treatment.

Drug treatment research: Experimental treatments aimed at suppressing osteochondroma growth through heparan sulfate replacement or modulation of IHH signaling are under study. The role of some molecular targeted agents such as imatinib in MCE is being explored at the preclinical research stage, but no clinically available drug exists to date.

11. Prognosis

The life expectancy of patients with multiple congenital exostoses is close to normal as long as malignant transformation does not occur. Most patients can lead independent social lives in adulthood with appropriate surgical treatment and surveillance for complications. However, owing to the nature of the disease, repeated surgical procedures, skeletal deformities, pain, and functional limitations negatively affect quality of life, and the physical and psychological burden is large, especially for those undergoing repeated surgery in childhood and adolescence.

Malignant transformation has the greatest impact on prognosis. The lifetime risk of chondrosarcoma is estimated at about 2–5% in patients with EXT1 variants and about 0.5–1% in patients with EXT2 variants. Malignant transformation mainly occurs in adulthood (20s–40s), and if detected early and treated with wide resection, the 5-year survival for low-grade chondrosarcoma (grade 1) is over 90%. However, high-grade (grade 2–3) or advanced chondrosarcoma has a poor prognosis (5-year survival 40–50%) and a high risk of recurrence. For this reason, regular MRI surveillance is central to MCE management.

Functional prognosis depends on the degree of skeletal deformity. With severe forearm deformity, impaired hand function may persist, and severe genu valgum leads to early osteoarthritis and gait disturbance. Minimizing deformity through early correction during growth (osteotomy, growth plate modulation) greatly improves long-term functional prognosis. Nerve and vascular compression complications mostly recover with prompt surgical treatment, but recovery is sometimes incomplete after severe nerve injury. Spinal cord compression can cause permanent neurological damage if treatment is delayed, so prompt diagnosis and treatment are essential.

As a regular follow-up schedule, clinical examination and radiological assessment (especially MRI of lesions close to the trunk) are recommended every 6–12 months in childhood and every 1–2 years in adulthood. Patient education (recognition of warning symptoms of malignant transformation: new pain, rapid increase in lesion size, soft tissue mass) is important for early detection.

12. Prevention

Primary prevention of multiple congenital exostoses (prevention of the disease itself) is achieved through genetic counseling and gene-based prevention strategies. When an affected patient plans to have children, a comprehensive discussion of the 50% risk of inheritance, phenotypic variability, risk of malignant transformation, and PGT and prenatal diagnosis options should take place through genetic counseling with a medical genetics specialist. In families with EXT1 variants, the risk of malignant transformation is high, so this should be fully considered when deciding about PGT.

Through preimplantation genetic testing (PGT), it is possible to implant only unaffected embryos, which theoretically completely prevents MCE in the child. Prenatal diagnosis (CVS or amniocentesis) to determine whether the fetus is affected is another option. Occurrence due to de novo mutations cannot be prevented, but confirming carrier status through molecular confirmation in families of MCE patients makes subsequent preventive approaches possible.

Secondary prevention (prevention of complications) in affected patients is achieved through regular surveillance and early correction. During growth (childhood to adolescence), whole-skeleton X-rays and clinical examination should be performed every 6–12 months to identify progression of skeletal deformities early and not miss the optimal timing for corrective surgery. Early detection of nerve or vascular compression and excision can prevent permanent nerve damage. In adulthood, the focus should be on early detection of chondrosarcoma through regular MRI, and patients and families are educated to recognize the warning symptoms of malignant transformation (new pain, sudden growth of a lesion, soft tissue mass, etc.) and to visit a medical institution promptly. Establishing and continually updating an individualized long-term management plan through a multidisciplinary team of orthopedics, medical genetics, and rehabilitation medicine is the best prevention strategy.

13. References

  1. Stickens D, Clines G, Burbee D, et al. The EXT2 multiple exostoses gene defines a family of putative tumour suppressor genes. Nat Genet. 1996;14(1):25-32. DOI: 10.1038/ng0996-25. PMID: 8782815.

  2. Wuyts W, Van Hul W, De Boulle K, et al. Mutations in the EXT1 and EXT2 genes in hereditary multiple exostoses. Am J Hum Genet. 1998;62(2):346-354. DOI: 10.1086/301726. PMID: 9463313.

  3. Wicklund CL, Pauli RM, Johnston D, Hecht JT. Natural history study of hereditary multiple exostoses. Am J Med Genet. 1995;55(1):43-46. DOI: 10.1002/ajmg.1320550113. PMID: 7702097.

  4. Bovée JV. Multiple osteochondromas. Orphanet J Rare Dis. 2008;3:3. DOI: 10.1186/1750-1172-3-3. PMID: 18271966.

  5. Pedrini E, Jennes I, Tremosini M, et al. Genotype-phenotype correlation study in 529 patients with multiple hereditary exostoses. J Bone Joint Surg Am. 2011;93(24):2294-2302. DOI: 10.2106/JBJS.J.00949. PMID: 22159860.

  6. Schmale GA, Conrad EU 3rd, Raskind WH. The natural history of hereditary multiple exostoses. J Bone Joint Surg Am. 1994;76(7):986-992. DOI: 10.2106/00004623-199407000-00005. PMID: 8027127.

  7. Trebicz-Geffen M, Robinson D, Evron Z, et al. The molecular and cellular basis of exostosis formation in hereditary multiple exostoses. Int J Exp Pathol. 2008;89(5):321-331. DOI: 10.1111/j.1365-2613.2008.00589.x. PMID: 18768009.

  8. Stieber JR, Dormans JP. Manifestations of hereditary multiple exostoses. J Am Acad Orthop Surg. 2005;13(2):110-120. DOI: 10.5435/00124635-200503000-00004. PMID: 15850362.

  9. Bernard MA, Hall CE, Hogue DA, et al. Diminished levels of the putative tumor suppressor proteins EXT1 and EXT2 in exostosis chondrocytes. Cell Motil Cytoskeleton. 2001;48(3):149-162. DOI: 10.1002/cm.1001. PMID: 11223945.

  10. Mortier GR, Cohn DH, Cormier-Daire V, et al. Nosology and classification of genetic skeletal disorders: 2019 revision. Am J Med Genet A. 2019;179(12):2393-2419. DOI: 10.1002/ajmg.a.61366. PMID: 31633310.